JP2004525922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525922A5 JP2004525922A5 JP2002573034A JP2002573034A JP2004525922A5 JP 2004525922 A5 JP2004525922 A5 JP 2004525922A5 JP 2002573034 A JP2002573034 A JP 2002573034A JP 2002573034 A JP2002573034 A JP 2002573034A JP 2004525922 A5 JP2004525922 A5 JP 2004525922A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- light chain
- agent
- amino acid
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 13
- 235000001014 amino acid Nutrition 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 230000005945 translocation Effects 0.000 claims 6
- 108030001720 Bontoxilysin Proteins 0.000 claims 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 4
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 4
- 229940053031 botulinum toxin Drugs 0.000 claims 4
- 229940094657 botulinum toxin type a Drugs 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 3
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims 2
- 229930182847 D-glutamic acid Natural products 0.000 claims 2
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 2
- 229930195709 D-tyrosine Natural products 0.000 claims 2
- 229930195710 D‐cysteine Natural products 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 108010086677 Gonadotropins Proteins 0.000 claims 2
- 102000006771 Gonadotropins Human genes 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 102000008238 LHRH Receptors Human genes 0.000 claims 2
- 108010021290 LHRH Receptors Proteins 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 210000000805 cytoplasm Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 239000002622 gonadotropin Substances 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229940118376 tetanus toxin Drugs 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/810,601 US6831059B2 (en) | 2000-10-20 | 2001-03-15 | Compositions and methods for treating gonadotrophin related illnesses |
| PCT/US2002/007379 WO2002074327A2 (en) | 2001-03-15 | 2002-03-11 | Compositions and methods for treating gonadotrophin related illnesses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010106073A Division JP2010174037A (ja) | 2001-03-15 | 2010-05-06 | ゴナドトロピン関連疾患を治療するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004525922A JP2004525922A (ja) | 2004-08-26 |
| JP2004525922A5 true JP2004525922A5 (enExample) | 2005-12-22 |
Family
ID=25204201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573034A Withdrawn JP2004525922A (ja) | 2001-03-15 | 2002-03-11 | ゴナドトロピン関連疾患を治療するための組成物および方法 |
| JP2010106073A Withdrawn JP2010174037A (ja) | 2001-03-15 | 2010-05-06 | ゴナドトロピン関連疾患を治療するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010106073A Withdrawn JP2010174037A (ja) | 2001-03-15 | 2010-05-06 | ゴナドトロピン関連疾患を治療するための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6831059B2 (enExample) |
| EP (1) | EP1368053A4 (enExample) |
| JP (2) | JP2004525922A (enExample) |
| WO (1) | WO2002074327A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7227010B2 (en) * | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| CA2380457A1 (en) * | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| CA2797652C (en) * | 2000-07-21 | 2016-03-08 | Revance Therapeutics, Inc. | Multi-component biological transport systems |
| US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| WO2002061064A2 (de) * | 2001-02-01 | 2002-08-08 | Roche Diagnostics Gmbh | Verfahren zur herstellung von rekombinantem trypsin |
| US8071550B2 (en) * | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| PT1729821E (pt) | 2004-03-03 | 2013-10-23 | Revance Therapeutics Inc | Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| EP1570855A1 (fr) * | 2004-03-04 | 2005-09-07 | Claude Le Louarn | Utilisation de toxine botulique pour préparer un médicament destiné à prévenir la pousse de poils |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US7811584B2 (en) | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US7897147B2 (en) * | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
| CA2588758C (en) * | 2004-11-22 | 2017-01-03 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8022179B2 (en) | 2005-03-03 | 2011-09-20 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| BRPI0608249A2 (pt) | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
| US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| DK1926744T4 (en) * | 2005-09-19 | 2019-01-28 | Allergan Inc | CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES |
| WO2007059528A2 (en) | 2005-11-17 | 2007-05-24 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
| EP2129402A2 (en) * | 2007-02-16 | 2009-12-09 | KTB Tumorforschungsgesellschaft mbH | Receptor and antigen targeted prodrug |
| EP3590956A1 (en) * | 2008-06-12 | 2020-01-08 | Ipsen Bioinnovation Limited | Suppression of neuroendocrine diseases |
| US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| ES2426667T3 (es) * | 2008-09-09 | 2013-10-24 | Susanne Grafe | Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano) |
| US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
| US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
| US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
| US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
| US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
| GB0820970D0 (en) * | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| ES2660901T3 (es) | 2012-04-13 | 2018-03-26 | Lubrizol Advanced Materials, Inc. | Compuestos que inhiben la exocitosis neuronal (II) |
| EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
| EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
| EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
| US9315549B2 (en) | 2013-01-28 | 2016-04-19 | New York University | Treatment methods using atoxic neurotoxin derivatives |
| EP3230457B1 (en) | 2014-12-09 | 2021-06-30 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
| JP2022530823A (ja) * | 2019-05-02 | 2022-07-01 | ザ・ユニバーシティ・オブ・シドニー | がん治療のためのペプチド誘導体とそのコンジュゲート |
| US11338016B2 (en) | 2020-05-20 | 2022-05-24 | Howard University | C-terminal fragment of tetanus toxin (Hc) for treatment of depression |
| WO2022019583A1 (ko) * | 2020-07-23 | 2022-01-27 | (주)메디톡스 | 엑소좀-매개된 질환 치료제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5186090A (en) | 1989-02-23 | 1990-09-26 | Colorado State University Research Foundation | Gnrh analogs for destroying gonadotrophs |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6005086A (en) | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US5939070A (en) | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
| US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
-
2001
- 2001-03-15 US US09/810,601 patent/US6831059B2/en not_active Expired - Lifetime
-
2002
- 2002-03-11 WO PCT/US2002/007379 patent/WO2002074327A2/en not_active Ceased
- 2002-03-11 EP EP02721347A patent/EP1368053A4/en not_active Ceased
- 2002-03-11 JP JP2002573034A patent/JP2004525922A/ja not_active Withdrawn
-
2010
- 2010-05-06 JP JP2010106073A patent/JP2010174037A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525922A5 (enExample) | ||
| AU2019218786B2 (en) | Cell-permeable stapled peptide modules for cellular delivery | |
| CN101815724B (zh) | 用于将轭合至其的试剂递送至组织的抑肽酶样多肽 | |
| McGonigle | Peptide therapeutics for CNS indications | |
| CN103402545B (zh) | 疏水性经修饰肽及其在肝特异性靶向中的用途 | |
| KR101155294B1 (ko) | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 | |
| EP2558503A1 (en) | Compositions and methods for brain delivery of analgesic peptides | |
| CN103080125A (zh) | 用于治疗性结合物的短且含d氨基酸的多肽及其使用 | |
| TW201333032A (zh) | 使用免疫球蛋白片段之位點專一性ｇｌｐ－２接合物 | |
| JP2006506942A5 (enExample) | ||
| WO2004064787A3 (en) | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus | |
| RU2002130203A (ru) | Пептидные конъюгаты для доставки лекарственного средства | |
| JP7767325B2 (ja) | Ｇｌｐ１ｒアゴニスト・ｎｍｄａｒアンタゴニストコンジュゲート | |
| US20230158100A1 (en) | Treatment of panx1 associates diseases | |
| CN111093701A (zh) | 含有抗globo h抗体的抗体药物偶联物及其用途 | |
| MXPA99010523A (es) | Metodos para mejorar el funcionamiento del tractogastrointestinal superior. | |
| JP2002525081A5 (enExample) | ||
| CN102076353A (zh) | 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽 | |
| DE69941877D1 (de) | Neovaskular-spezifische peptide | |
| JP7239987B2 (ja) | 薬物送達のための抗体融合タンパク質 | |
| CN118510545A (zh) | 用于治疗神经退行性疾病的肽-药物缀合物 | |
| KR20110028433A (ko) | 엔케팔린 분해 엑토펩티다제의 강력한 억제제로서의 오피올핀 펩타이드 유도체 | |
| JP7785543B2 (ja) | 構造的に明確なｓｉＲＮＡ－二重可変ドメイン免疫グロブリンコンジュゲート | |
| Merani et al. | Development of a sensitive and specific assay system for cholecystokinin tetrapeptide | |
| EP4667483A1 (en) | Human transferrin receptor-binding peptide |